These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 24329787)

  • 1. Adoptive immunotherapy for cancer.
    Ruella M; Kalos M
    Immunol Rev; 2014 Jan; 257(1):14-38. PubMed ID: 24329787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C; Zhao Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. gammadelta T cells in cancer immunotherapy: current status and future prospects.
    Chiplunkar S; Dhar S; Wesch D; Kabelitz D
    Immunotherapy; 2009 Jul; 1(4):663-78. PubMed ID: 20635991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive cellular immunotherapy for childhood malignancies.
    Cooper LJ
    Bone Marrow Transplant; 2008 Jan; 41(2):183-92. PubMed ID: 18026145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting cytokines in adoptive T-cell therapy of cancer.
    Petrozziello E; Sturmheit T; Mondino A
    Immunotherapy; 2015; 7(5):573-84. PubMed ID: 26065481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive T-cell therapy of cancer.
    Erbayraktar Z
    J BUON; 2009 Sep; 14 Suppl 1():S193-201. PubMed ID: 19785066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of memory T cell subsets for adoptive immunotherapy.
    Busch DH; Fräßle SP; Sommermeyer D; Buchholz VR; Riddell SR
    Semin Immunol; 2016 Feb; 28(1):28-34. PubMed ID: 26976826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of endogenous T cells for adoptive transfer.
    Yee C
    Immunol Rev; 2014 Jan; 257(1):250-63. PubMed ID: 24329802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive T-Cell Therapy for Solid Malignancies.
    Jafferji MS; Yang JC
    Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy for cancer or viruses.
    Maus MV; Fraietta JA; Levine BL; Kalos M; Zhao Y; June CH
    Annu Rev Immunol; 2014; 32():189-225. PubMed ID: 24423116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
    Berry LJ; Moeller M; Darcy PK
    Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling.
    Ribas A; Koya RC
    Future Oncol; 2010 Nov; 6(11):1671-3. PubMed ID: 21142653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.